Skip to main content

MOUD Programs After the 2024 Part 8 Rule: What Tracking Has to Cover

Jeremy Bloom, Co-founder · · Updated

An opioid treatment program may use only a medication for opioid use disorder that the FDA has approved under 21 U.S.C. 355 for use in the treatment of opioid use disorder, or a drug the FDA has authorized under an investigational new drug application under section 505(i) of the Federal Food, Drug, and Cosmetic Act for investigational use in the treatment of opioid use disorder, when the program is fully compliant with the protocol of that investigational use and the other conditions in the application [1]. The medications the rule currently treats as approved are methadone, buprenorphine and buprenorphine combination products that have been approved for use in the treatment of opioid use disorder, and naltrexone [1]. SAMHSA’s Part 8 page says the revised rule was released in February 2024, took effect on April 2, 2024, and set a compliance date of October 2, 2024 [2]. The current standards are in 42 CFR 8.12 [1].

This post is about what an OTP has to track after that revision, and about the separate change to who may prescribe buprenorphine outside the old waiver. It does not claim that any software product improves outcomes.

Take-home doses are a clinical decision with statutory caps

Since the 2024 revision of 42 CFR Part 8, take-home doses of methadone are decided by the program’s medical practitioner against criteria in § 8.12 rather than by time in treatment alone, with supply limits that change at 15 days of treatment and again at 31 days [1].

A patient admitted under § 8.12(e)(1) may receive individualized take-home doses for days the clinic is closed for business, including one weekend day and state and federal holidays, no matter how long the patient has been in treatment [1]. A patient in interim treatment receives those same closed-clinic doses, because § 8.12(j)(4) applies every requirement of that treatment to interim treatment except for the exceptions that paragraph lists [1]. Beyond that, an appropriately licensed program medical practitioner or the medical director decides unsupervised doses by weighing benefits against risks. The criteria in § 8.12(i)(2) are the absence of active substance use disorders and of other physical or behavioral health conditions that increase the risk of patient harm as it relates to the potential for overdose or to the ability to function safely; regularity of attendance for supervised medication administration; the absence of serious behavioral problems that endanger the patient, the public, or others; the absence of known recent diversion activity; whether the take-home medication can be safely transported and stored; and any other criterion the medical director or medical practitioner considers relevant to the patient’s safety and the public’s health [1]. The decision and its basis go in the record [1].

If the practitioner determines the patient can manage unsupervised methadone, the supply limits are [1]:

  • During the first 14 days of treatment, the take-home supply beyond closed-clinic days is limited to 7 days [1].
  • From 15 days of treatment, that supply is limited to 14 days [1].
  • From 31 days of treatment, the supply is not to exceed 28 days [1].

The practitioner still chooses the number up to the cap. The caps do not apply to buprenorphine or to the buprenorphine combination products listed in § 8.12(h)(2)(ii) [1]. The program must maintain current procedures adequate to identify the theft or diversion of take-home medication, including labeling containers with the program’s name, address, and telephone number [1]. It must ensure that each take-home dose is packaged to reduce the risk of accidental ingestion, including a child-proof container [1]. It must educate each patient on safely transporting the medication from the program to the patient’s residence and on storing take-home doses there, including child and household safety precautions, and that education should be documented in the clinical record [1]. A chart that advances a “phase” because a calendar date arrived, without the § 8.12(i)(2) criteria and a documented rationale, is following a schedule the current rule does not use [1].

Other OTP facts the record has to hold

Section 8.12 also sets documentation that is easy to miss when a template is built around phases [1]:

  • Qualified personnel admit the patient using accepted medical criteria, and they document that the person meets diagnostic criteria for a moderate to severe opioid use disorder and has an active moderate to severe disorder, a disorder in remission, or a high risk of recurrence or overdose [1]. A health care practitioner ensures that the patient voluntarily chooses treatment with a medication for opioid use disorder, that all relevant facts about the use of that medication are clearly and adequately explained, and that the patient gives informed consent to treatment [1]. Except in states where state law lets a person under 18 consent to opioid treatment program treatment without another person’s consent, no one under 18 is admitted unless a parent, legal guardian, or responsible adult designated by the relevant state authority consents in writing to that treatment [1]. The program must maintain current policies and procedures that reflect the special needs of pregnant patients with opioid use disorder and give them priority for admission [1]. Pregnancy should be confirmed [1]. An evidence-based protocol for a pregnant patient, such as split dosing, may be instituted after a program practitioner assesses it and documents that it is clinically appropriate [1]. Prenatal care and other sex-specific services, including reproductive health services, for pregnant and postpartum patients must be provided and documented by the program or by referral to an appropriate health care practitioner [1].
  • For each new patient, the initial methadone dose shall be individually determined and shall include consideration of the types of opioids involved in the patient’s opioid use disorder, other medications or substances being taken, the medical history, and the severity of opioid withdrawal [1]. The total dose for the first day should not exceed 50 milligrams unless a program practitioner who is licensed under state law and registered under state and federal law to administer or dispense the medication finds sufficient medical rationale, including, but not limited to, a patient transferring from another opioid treatment program on a higher dose that has been verified, and documents in the record that a higher dose was clinically indicated [1]. The program shall maintain current procedures adequate to ensure that methadone is administered or dispensed only in oral form and is formulated to reduce its potential for parenteral misuse, and that each medication for opioid use disorder the program uses is administered and dispensed in accordance with its FDA-approved product labeling [1]. The program must ensure that any significant deviation from that labeling, including a deviation in dose, frequency, or the conditions of use described in the labeling, is specifically documented in the patient’s record [1]. The program must ensure that the medication is administered or dispensed only by a practitioner licensed under state law and registered under state and federal law to do so, or by an agent of that practitioner, supervised by and under the order of the practitioner, when that is consistent with federal and state law [1].
  • The initial medical examination has two parts: a screening examination to confirm that the patient meets criteria for admission and that there are no contraindications to treatment with a medication for opioid use disorder, and a full history and examination of the patient’s broader health status, with the lab testing an appropriately licensed practitioner requires [1]. If there are no contraindications, the patient may start the medication after the screening examination is completed [1]. A patient’s refusal of lab testing for a co-occurring physical health condition should not preclude access to treatment, if that refusal does not have the potential to negatively affect treatment with the medication [1]. Both the screening examination and the full examination must be completed by an appropriately licensed practitioner [1]. If that practitioner is not a program practitioner, the screening examination must be completed no more than seven days before admission [1]. When an examination is performed outside the program, the written results and narrative, and the available lab results, must be transmitted consistent with applicable privacy laws and verified by a program practitioner [1]. A full in-person physical examination, including the results of serology and other tests that are clinically appropriate, must be completed within 14 calendar days of admission [1]. A practitioner outside the program may complete it if a licensed program practitioner verifies that the exam is true and accurate and the results are transmitted under applicable privacy laws [1]. For a patient admitted for methadone or buprenorphine, the screening and the full examination may be done by telehealth when a practitioner or primary care provider determines that telehealth is an adequate evaluation [1]. A Schedule II medication, such as methadone, requires an audio-visual platform, except when that platform is not available to the patient. Audio-only is acceptable then only when the patient is in the presence of a licensed practitioner registered to prescribe, including to dispense, controlled medications [1]. A Schedule III medication, such as buprenorphine, or a medication that is not a controlled medication, such as naltrexone, may use an audio-visual or audio-only platform [1]. The program practitioner shall review the examination results and order treatment medications as indicated [1]. A periodic physical examination should occur at least once a year, be conducted by a program practitioner, and be written in the clinical record [1]. It should include review of the medication dose, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical and psychiatric treatment needs and goals [1].
  • Each patient admitted to the program shall be given a physical and behavioral health assessment within 14 calendar days of admission, and periodically after that, by appropriately licensed or credentialed personnel [1]. That assessment includes, but is not limited to, screening for imminent risk of harm to self or others [1]. These assessments must address the need for treatment or the response to treatment, adjust treatment interventions, including the medication, as necessary, and provide a patient-centered plan of care [1]. The full initial psychosocial assessment must be completed within 14 calendar days of admission and include preparation of a care plan that includes the patient’s goals and the mutually agreed actions for the patient to meet those goals, including harm-reduction interventions; the patient’s needs and goals in the areas of education, vocational training, and employment; and the medical and psychiatric, psychosocial, economic, legal, housing, and other recovery support services the patient needs and wishes to pursue [1]. The care plan also must identify the recommended frequency with which those services are provided. It must be reviewed and updated to reflect responses to treatment and recovery support services, and adjusted for changes in the context of the person’s life, their current needs for and interests in medical, psychiatric, social, and psychological services, and their current needs for and interests in education, vocational training, and employment services [1].
  • When the program conducts random drug testing, it must use tests that have FDA marketing authorization for commonly used and misused substances that may affect patient safety, recovery, or otherwise complicate substance use disorder treatment, at a frequency consistent with generally accepted clinical practice and as indicated by the patient’s response to and stability in treatment, but no fewer than eight random drug tests per patient per year, allowing for extenuating circumstances for that patient [1].
  • The program shall provide adequate medical, counseling, vocational, educational, and other screening, assessment, and treatment services to meet patient needs. The combination and frequency are tailored to each patient based on an individualized assessment and a care plan created after shared decision making between the patient and the clinical team [1]. Those services must be available at the primary facility, unless the program sponsor has a documented agreement with a private or public agency, organization, practitioner, or institution to provide them to patients enrolled in the program [1]. The sponsor must be able to document that these services are fully and reasonably available to patients [1].
  • The program must provide adequate substance use disorder counseling and psychoeducation to each patient as clinically necessary and mutually agreed, including harm-reduction education and recovery-oriented counseling [1]. That counseling shall be provided by a program counselor qualified by education, training, or experience to assess the patient’s psychological and sociological background, to engage with the patient, to contribute to the care plan, and to monitor and update progress [1]. A patient’s refusal of counseling shall not preclude the patient from receiving the medication [1]. The program must provide counseling on preventing exposure to, and the transmission of, HIV, viral hepatitis, and sexually transmitted infections, and it either directly provides services and treatments or actively links to treatment each patient admitted or readmitted who has received a positive test result for one of those conditions from an initial or periodic medical examination [1]. The program must provide vocational training, education, and employment services directly, or by referral to adequate and reasonably accessible community resources, when the patient requests them or when the patient and program staff have identified those needs and agreed they are beneficial [1].
  • The program shall maintain current procedures designed to ensure that patients who choose to taper off the medication are given that chance with informed consent, at a mutually agreed rate that minimizes taper-related risks, and the treating practitioner must document that consent in the clinical record [1].

OTPs must keep a recordkeeping system adequate to document and monitor patient care [1]. That system must comply with all federal and state reporting requirements relevant to medications for opioid use disorder approved for use in treatment of opioid use disorder, and all records must be kept confidential in accordance with all applicable federal and state requirements [1]. As an essential part of that system, the program must document in each patient’s record a good-faith effort to determine whether the patient is enrolled in any other opioid treatment program [1]. A patient enrolled in one program may not obtain treatment in another, except when the patient cannot access care at the program of record. Those circumstances include, but are not limited to, travel for work or family events, a temporary relocation, or the program’s temporary closure [1]. If the medical director or program practitioner of the program in which the patient is enrolled finds that those circumstances exist, the patient may get treatment at another program, and the justification for those circumstances is written in the patient’s record at the program of enrollment and at the program that will provide the medication [1]. Section 8.12(c) requires current quality-assurance and quality-control plans that include, among other things, annual reviews of program policies and procedures and ongoing assessment of patient outcomes, and a current diversion-control plan as part of the quality-assurance program [1]. That plan must contain specific measures to reduce the possibility of diversion of dispensed medication and must assign specific responsibility to the program’s providers and administrative staff for carrying out those measures and the functions the plan describes [1]. Section 8.12(d) requires each person engaged in the treatment of opioid use disorder to have sufficient education, training, and experience, or any combination of those, to perform the assigned functions [1]. Practitioners and other licensed or certified health care providers, including counselors, must comply with the credentialing requirements of their professions and with the requirements for maintaining that licensure or certification [1]. Section 8.12(a) requires the program to provide treatment in accordance with the standards in that section, and following those standards is a condition of certification [1]. Section 8.12(b) requires the program’s organizational structure and facilities to be adequate for quality patient care and for the requirements of pertinent federal, state, and local laws [1]. At a minimum, the program must formally designate a program sponsor and a medical director [1]. The sponsor agrees, on behalf of the program, to adhere to every requirement in 42 CFR part 8 [1]. The medical director assumes responsibility for all medical and behavioral health services the program performs, and for ensuring that the program follows applicable federal, state, and local laws [1].

OTPs are commonly Part 2 programs because they are federally assisted substance use disorder programs. The use and disclosure restrictions cover a record that would identify a patient as having or having had a substance use disorder, either directly, by reference to publicly available information, or through verification of that identification by another person and that contains substance use disorder information obtained by a federally assisted substance use disorder program after March 20, 1972, or alcohol use disorder information obtained after May 13, 1974 by a federally assisted alcohol use disorder or substance use disorder program, for the purpose of treating a substance use disorder, making a diagnosis for that treatment, or making a referral for that treatment [3]. Information obtained before the pertinent date is covered when a part 2 program maintains it after that date as part of an ongoing treatment episode that extends past that date [3]. A separate restriction bars using substance use disorder information, whether or not it is recorded, to initiate or substantiate criminal charges against a patient or to conduct a criminal investigation of a patient, when a federally assisted substance use disorder program obtained that information after March 20, 1972, or a federally assisted alcohol use disorder or substance use disorder program obtained the alcohol use disorder information after May 13, 1974, for the purpose of treating a substance use disorder, making a diagnosis for the treatment, or making a referral for the treatment [3]. Information obtained before the pertinent date is covered by that restriction when a part 2 program maintains it after that date as part of an ongoing treatment episode that extends past that date [3]. It does not follow that every staff person needs a fresh consent to see the chart they need for their job.

42 CFR 2.12(c)(3) says the restrictions do not apply to communications of information between or among personnel having a need for the information in connection with their duties that arise out of the provision of diagnosis, treatment, or referral for treatment of patients with substance use disorders, if the communications are within a Part 2 program or between a Part 2 program and an entity that has direct administrative control over the program [3]. A duty that is merely inside the program is not enough. Someone outside the program is not covered. Access should still be limited by role. The exception is not a reason to open every MAT field to every login.

For disclosures that do need consent, 42 CFR 2.33 allows a single consent for all future uses and disclosures for treatment, payment, and health care operations, until the patient revokes it in writing [4]. When those records are disclosed for treatment, payment, and health care operations to a covered entity or business associate, that recipient may further disclose them in accordance with the HIPAA regulations, except for uses and disclosures for civil, criminal, administrative, and legislative proceedings against the patient [4]. A template that still says every disclosure needs its own consent is describing the rule before this section.

The separate waiver for buprenorphine prescribing

The X-waiver lived in the Controlled Substances Act as a waiver of registration requirements for practitioners treating opioid use disorder with certain narcotic drugs. The Part 8 final rule states that the Consolidated Appropriations Act, 2023 (Public Law 117-328) eliminated that waiver, commonly called the DATA-waiver, and that section 1262 removed the requirement to obtain a waiver before prescribing buprenorphine for opioid use disorder [6]. The notes to 21 U.S.C. § 823 record that section 1262(a) of that law struck the paragraph that contained the waiver [5]. Section 1263(a) of the same law added the prescriber-training requirement, later redesignated as subsection (m) [5].

Current § 823(m) makes a listed credential or training a condition of registration to dispense controlled substances in schedule II, III, IV, or V [5]. The Attorney General requires that condition of any qualified practitioner, beginning with the first applicable registration [5]. A qualified practitioner is licensed under state law to prescribe controlled substances and is not solely a veterinarian [5]. The first applicable registration is the first registration or renewal on or after the date 180 days after December 29, 2022 [5]. A physician meets one or more of these conditions: a board certification in addiction psychiatry or addiction medicine from the American Board of Medical Specialties; a board certification from the American Board of Addiction Medicine; a board certification in addiction medicine from the American Osteopathic Association; not less than 8 hours of training, from organizations the statute lists, on the treatment and management of patients with opioid or other substance use disorders, or on the safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid or other substance use disorders; or graduation in good standing, during the five-year period immediately before the physician first registers or renews, from an accredited school of allopathic medicine, osteopathic medicine, podiatric medicine, dental surgery, or dental medicine in the United States, together with successful completion of the allopathic or osteopathic medicine curriculum, an accredited medical residency, or a dental surgery, dental, or podiatric medicine curriculum that § 823(m)(1)(A)(v) describes, including not less than 8 hours of training on treating and managing patients with opioid or other substance use disorders, including the appropriate clinical use of all drugs the FDA has approved for the treatment of a substance use disorder, or on the safe pharmacological management of dental pain and screening, brief intervention, and referral for appropriate treatment of patients with or at risk of developing opioid and other substance use disorders [5]. A practitioner who is not a physician must be legally authorized by the state to dispense controlled substances in schedule II, III, IV, or V and must be dispensing those substances in that state in accordance with applicable state law [5]. That practitioner then meets one or more of these conditions: not fewer than 8 hours of training, from organizations the statute lists, on the treatment and management of patients with opioid or other substance use disorders; or graduation in good standing, during the five-year period immediately before the practitioner first registers or renews, from an accredited physician assistant school, an accredited school of advanced practice nursing, or an accredited school of pharmacy in the United States, together with successful completion of the physician assistant or advanced practice nursing curriculum that § 823(m)(1)(B)(ii) describes, including not fewer than 8 hours of training on treating and managing patients with opioid and other substance use disorders, including the appropriate clinical use of all drugs the FDA has approved for the treatment of a substance use disorder [5]. The Attorney General shall not require a qualified practitioner to complete the training in § 823(m)(1)(A)(iv) or (v), or in § 823(m)(1)(B)(i) or (ii), more than once [5]. That paragraph is titled one-time training [5].

That change is about who may prescribe. It does not replace Part 8 for an OTP’s methadone practice, and it does not replace the take-home criteria in § 8.12 [1, 5].

Sources

  1. 42 CFR 8.12, federal opioid use disorder treatment standards, Office of the Federal Register, eCFR. Accessed September 29, 2026.
  2. 42 CFR Part 8 final rule: effective and compliance dates, Substance Abuse and Mental Health Services Administration. Accessed September 28, 2026.
  3. 42 CFR 2.12, applicability, including communications inside a Part 2 program, Office of the Federal Register, eCFR. Accessed September 28, 2026.
  4. 42 CFR 2.33, uses and disclosures permitted with written consent, Office of the Federal Register, eCFR. Accessed September 28, 2026.
  5. 21 U.S.C. 823, including the training requirement and the amendment notes on the former waiver, Legal Information Institute, Cornell Law School. Accessed September 28, 2026.
  6. Medications for the Treatment of Opioid Use Disorder, final rule, Office of the Federal Register. Accessed September 28, 2026.

On Encore OS, assessments, treatment plans and progress notes sit on the shared encounter, and 42 CFR Part 2 consent is captured with redisclosure tracking.

Residential treatment on Encore OS